[C:1]([O:5][C:6]([N:8]1[CH2:12][CH2:11][CH2:10][C@H:9]1[C:13]([OH:15])=[O:14])=[O:7])([CH3:4])([CH3:3])[CH3:2].CN(C(ON1N=NC2[CH:27]=[CH:28][CH:29]=[N:30]C1=2)=[N+](C)C)C.F[P-](F)(F)(F)(F)F.CCN(C(C)C)C(C)C.[NH2:49][C:50]1[S:51][CH:52]=[C:53]([C:55]2[CH:63]=[CH:62][C:58]([C:59]([OH:61])=[O:60])=[CH:57][CH:56]=2)[N:54]=1>CN(C=O)C>[C:1]([O:5][C:6]([N:8]1[CH2:12][CH2:11][CH2:10][C@H:9]1[C:13](=[O:15])[NH:49][C:50]1[S:51][CH:52]=[C:53]([C:55]2[CH:56]=[CH:57][C:58]([C:59](=[O:61])[NH:30][CH:29]3[CH2:27][CH2:28]3)=[CH:62][CH:63]=2)[N:54]=1)=[O:7])([CH3:2])([CH3:3])[CH3:4].[C:1]([O:5][C:6]([N:8]1[CH2:12][CH2:11][CH2:10][C@H:9]1[C:13](=[O:14])[NH:49][C:50]1[S:51][CH:52]=[C:53]([C:55]2[CH:56]=[CH:57][C:58]([C:59]([OH:61])=[O:60])=[CH:62][CH:63]=2)[N:54]=1)=[O:7])([CH3:4])([CH3:3])[CH3:2]A mixture of (S)-pyrrolidine-1,2-dicarboxylic acid 1-tertbutyl ester (1.30 g, 6.04 mmol), HATU (2.31 g, 6.07 mmol)), and DIEA (1.2 mL, 9.18 mmol) in DMF (32 mL) was stirred at room temperature for 1 h. Then 4-(2-amino-thiazol-4-yl)-benzoic acid (0.89 g, 4.04 mmol) was added and the reaction mixture was stirred at room temperature overnight. The resulting mixture was purified by reverse phase HPLC to furnish the desired product (S)-2-[4-(4-carboxy-phenyl)-thiazol-2-ylcarbamoyl]-pyrrolidine-1-carboxylic acid tert-butyl ester; MS: 418.1 (M+H+).